Core Viewpoint - The stock of Boteng Co., Ltd. has experienced fluctuations, with a year-to-date increase of 52.82% and a recent decline of 15.70% over the past 20 days [1][2] Financial Performance - For the first half of 2025, Boteng Co., Ltd. achieved a revenue of 1.621 billion yuan, representing a year-on-year growth of 19.88% - The net profit attributable to shareholders was 27.0595 million yuan, showing a significant increase of 115.91% year-on-year [2] Shareholder Information - As of October 10, 2025, the number of shareholders for Boteng Co., Ltd. was 50,100, a decrease of 2.75% from the previous period - The average number of circulating shares per shareholder increased by 2.83% to 9,983 shares [2] Dividend Distribution - Since its A-share listing, Boteng Co., Ltd. has distributed a total of 1.193 billion yuan in dividends, with 866 million yuan distributed over the past three years [3] Institutional Holdings - As of June 30, 2025, the top ten circulating shareholders included Hong Kong Central Clearing Limited, which increased its holdings by 2.3886 million shares to 10.7589 million shares - Tianhong Medical Innovation A reduced its holdings by 513,900 shares to 6.398 million shares, while Southern CSI 1000 ETF entered the top ten shareholders with 3.0218 million shares [3]

Core Insights - On October 20, 2023, Boteng Co., Ltd. saw a stock price increase of 2.59% with a trading volume of 336 million yuan [1] - The company reported a financing buy-in amount of 37.97 million yuan and a net financing buy of 642.37 thousand yuan on the same day [1][2] - As of October 20, the total margin balance for Boteng Co., Ltd. was 501 million yuan, representing 3.73% of its market capitalization [1] Financing and Margin Trading - On October 20, the financing buy-in for Boteng Co., Ltd. was 37.97 million yuan, with a current financing balance of 500 million yuan, which is above the 80th percentile of the past year [1] - The company had a margin repayment of 800 shares and a margin sell of 600 shares, with a margin balance of 686.3 thousand yuan, indicating a low level compared to the past year [1] Business Performance - For the first half of 2025, Boteng Co., Ltd. achieved a revenue of 1.621 billion yuan, marking a year-on-year growth of 19.88% [2] - The net profit attributable to shareholders for the same period was 27.06 million yuan, reflecting a significant year-on-year increase of 115.91% [2] Shareholder Information - As of October 10, 2023, the number of shareholders for Boteng Co., Ltd. was 50,100, a decrease of 2.75% from the previous period [2] - The average number of circulating shares per shareholder increased by 2.83% to 9,983 shares [2] Dividend Distribution - Since its A-share listing, Boteng Co., Ltd. has distributed a total of 1.193 billion yuan in dividends, with 866 million yuan distributed over the past three years [3] Institutional Holdings - As of June 30, 2025, Hong Kong Central Clearing Limited was the fifth-largest circulating shareholder, holding 10.7589 million shares, an increase of 2.3886 million shares from the previous period [3] - Tianhong Medical Innovation A was the sixth-largest circulating shareholder, holding 6.398 million shares, a decrease of 513.9 thousand shares [3] - New institutional shareholders included Southern CSI 1000 ETF, which held 3.0218 million shares [3]

9月12日，博腾股份盘中下跌2.03%，截至10:02，报25.06元/股，成交1.89亿元，换手率1.48%，总市值 136.69亿元。 资金流向方面，主力资金净流出1596.03万元，特大单买入334.17万元，占比1.76%，卖出814.07万元， 占比4.30%；大单买入2986.50万元，占比15.77%，卖出4102.63万元，占比21.67%。 博腾股份今年以来股价涨58.91%，近5个交易日跌3.24%，近20日涨5.21%，近60日涨62.10%。 博腾股份所属申万行业为：医药生物-医疗服务-医疗研发外包。所属概念板块包括：CRO概念、抗癌治 癌、抗癌药物、创新药、生物医药等。 截至8月29日，博腾股份股东户数5.27万，较上期减少0.75%；人均流通股9502股，较上期增加0.75%。 2025年1月-6月，博腾股份实现营业收入16.21亿元，同比增长19.88%；归母净利润2705.95万元，同比增 长115.91%。 分红方面，博腾股份A股上市后累计派现11.93亿元。近三年，累计派现8.66亿元。 机构持仓方面，截止2025年6月30日，博腾股份十大流通股东中，香港中央结算有限公司位 ...